Objective: IGF1 and its most abundant binding protein, IGF-binding protein 3 (IGFBP3), have been implicated in fibrotic lung diseases and persistent acute respiratory distress syndrome (ARDS) due to profibrogenic and antiapoptotic activity. Whether circulating levels of IGF1 and IGFBP3 are altered in ARDS and whether they predict progression of and survival from ARDS remains unknown. This study aims to characterize the circulating levels of IGF1 and IGFBP3 in patients at risk for ARDS in relation to i) development of ARDS and ii) mortality among ARDS cases. Design: In this case-cohort study, consecutive patients with risk factors for ARDS admitted to the intensive care unit were enrolled and followed prospectively for the development of ARDS. Cases were followed for all-cause mortality through day 60. Of the 2397 patients enrolled in the parent study, plasma samples were available in 531 (22%) patients (356 controls and 175 cases) from early in presentation. Total plasma IGF1 and IGFBP3 levels were measured. Results: After adjusting for relevant clinical covariates including severity of illness, IGF1 and IGFBP3 levels were significantly lower in ARDS cases than in controls (odds ratio (OR), 0.58; PZ0.006; OR, 0.57; PZ0.0015 respectively). Among the ARDS cases, IGF1 and IGFBP3 levels were significantly lower in the 78 (45%) non-survivors (hazard ratio (HR), 0.70; PZ0.024; HR, 0.69; PZ0.021 respectively). Conclusions: Lower circulating levels of IGF1 and IGFBP3 were independently associated with ARDS case status. Furthermore, lower levels were associated with mortality among the ARDS cases. These data support the role of the IGF pathway in ARDS.
Introduction
Insulin-like growth factor 1 (IGF1) is a strongly profibrogenic peptide with mitogenic and antiapoptotic effects (1) . It has been identified as a potential mediator of fibrotic lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis (2) (3) (4) (5) . IGF1 bioavailability is tightly regulated by at least six high-affinity IGFbinding proteins (IGFBPs) that directly modify the cellular actions of IGF1. IGFBP3 is most abundant in serum and has been shown to increase collagen and fibronectin synthesis by fibroblasts in vitro, even independent of IGF1 (6) . Studies on the IGF pathway in fibrotic lung disease report increased levels of IGF1 and IGFBP3 in lung. IGF1 also plays a critical role in fetal lung development, and IGF-mediated postnatal lung growth is associated with increased alveolar numbers and size (7) . IGF1 is also an endocrine mediator of GH-induced metabolic and anabolic actions, and it has paracrine and autocrine functions. Circulating IGF1 level is mainly controlled by GH secretion, and levels are also predicted by age, gender, smoking status, and dietary intake (8, 9) . Cytokines and genetic factors may also influence both circulating levels and local levels in the lung (10) . In general, acute critical illness is characterized by an increase in circulating GH levels and a decrease in IGF1 levels, indicative of relative GH resistance (11) . This GH resistance is thought to be at least partially responsible for the negative nitrogen balance seen in critical illness that affects organ function, including that of the respiratory muscles (12) .
The acute respiratory distress syndrome (ARDS) is an inflammatory insult to the lung that can progress to a persistent, or fibroproliferative, phase of ongoing inflammation on a backdrop of fibrosis. Given the role of the IGF pathway in fibroblast activation and collagen synthesis, there is some evidence for a role in the pathogenesis of ARDS. Increased IGFBP3 levels have been identified in bronchoalveolar lavage (BAL) fluid of ARDS patients and patients with risk factors for ARDS (13) . Enhanced immunostaining for IGF1 and its receptor (IGF1R) has been identified in lung biopsy specimens from patients with fibroproliferative ARDS (14) . Systemically, low serum IGF1 has been associated with bronchopulmonary dysplasia in premature infants, a disease with phenotypic similarities to ARDS, including exuberant inflammation, abnormal healing, and fibrosis (10) . There are no studies, however, examining circulating levels of IGF1 and IGFBP3 in ARDS specifically. This syndrome is a unique overlap of the systemic alterations of critical illness with injury and repair within the lung. Given previous studies on the GH pathway in critical illness, along with additional studies of the role of IGF1 in lung disease, we hypothesize that serum levels of IGF1 and IGFBP3 will be decreased in patients with ARDS compared with at-risk controls. Furthermore, we hypothesize that lower IGF1 and IGFBP3 levels will be associated with the outcome of mortality among ARDS cases.
Subjects and methods

Study population and design
This study is a case-cohort study that is part of the larger Molecular Epidemiology of ARDS Study for which study design and exclusion criteria have been thoroughly described previously (15) . The Human Subjects Committees at Massachusetts General Hospital, Beth Israel-Deaconess Medical Center, the Harvard School of Public Health, and the Yale School of Medicine approved this study. Recruitment of adult for intensive care unit (ICU) admissions at MGH (Boston, MA, USA) began in January 1999 and at BIDMC (Boston, MA, USA) in January 2007. The enrollment continued through March 2009. Admissions were screened daily for clinical risk factors for ARDS: pneumonia, sepsis or septic shock, aspiration, massive transfusions, pulmonary contusion, or multiple fractures. Patients with ARDS risk factors were followed prospectively for the development of ARDS. Controls were at-risk patients who did not develop ARDS. Patients were defined as having ARDS if they met the American-European Consensus Conference (AECC) criteria for ARDS and required intubation and mechanical ventilation (16) . Day 0 of ARDS was defined as the day on which the patient first met all AECC criteria simultaneously. The primary outcome was the development of ARDS. The secondary outcome among the ARDS cases was all-cause 60-day mortality.
Analysis of total IGF1 and IGFBP3 levels in plasma
Blood drawn within the target window was around the first 48 h of ICU admission; for patients developing ARDS beyond the first 2 days in the ICU, blood drawn was also targeted for the first 48 h of meeting the ARDS case definition. For the current study, control samples were included if they were drawn on day 0, 1, or 2 of ICU admission. Case samples were included if they were drawn within 2 days before or after day 0 of ARDS. The timing of these case samples was also analyzed to determine how many of these specimens also coincided with day 0, 1, or 2 of ICU admission. Timeto-measurement was considered in days, relative to day 0 as defined above. Patients whose blood samples did not conform to these parameters were excluded.
Blood samples were collected in 10 ml vacuum tubes and centrifuged for 10 min. Plasma samples were stored at K80 8C until analysis. Total IGF1 and IGFBP3 levels were measured using an automated IMMULITE assay on an IMMULITE 1000 instrument (Siemens, Malvern, PA, USA). For IGF1 and IGFBP3, the assay sensitivity was 20 ng/ml and 0.1 mg/ml, the high-dose hook effect was at 45 000 ng/ml and 426 mg/ml, and the intraassay variability was 3.56 and 4.20% respectively. Samples were run in duplicates, and measurements with a coefficient of variation higher than 15% were rejected and the samples were reanalyzed. Lab personnel were blinded to case-control status and clinical information. Because this nested study was part of a larger genetic study, only Caucasians were included in this study. Caucasians comprised O90% of the parent cohort. GH is secreted in pulsatile fashion, and its levels display day-to-night rhythmicity. An accurate assessment of GH levels would require frequent (every 10 min) sampling for 24 h, which was not feasible in the context of this study.
Statistical analysis
All statistical analyses were performed using SAS Version 9.2 (SAS, Inc., Cary, NC, USA).
Demographic and clinical characteristics between groups were compared using c 2 tests for categorical variables and Student's t-tests and/or nonparametric tests for continuous variables. Correlations between serum IGF1 and IGFBP3 and clinical variables were estimated using the Spearman correlation.
IGF1 and IGFBP3 were log-transformed to approximate normality, and log-transformed values were used in all models. Logistic regression models were used to assess the association of IGF1 and IGFBP3 with ARDS case status. Cox proportional hazard models were used to assess the association between IGF1 and IGFBP3 levels and survival. All multivariable models used a backward selection algorithm with P%0.1 to stay; models were then refit with the surviving covariates.
Multivariable models considered the following clinically relevant covariates: age, gender, APACHE III score, body mass index (BMI), risk factor for ARDS, smoking status, and current history of cirrhosis or diabetes. The risk factor for ARDS was represented by the following individual covariates: sepsis, septic shock, direct pulmonary injury (defined as pneumonia, aspiration, or pulmonary contusion), trauma, and need for red blood cell transfusions. In multivariate analyses of ARDS case status, the APACHE III score excluded P a O 2 /F i O 2 to avoid collinearity (17) . Given evidence that sex hormones may be an effect modifier, exogenous estrogen or progestin use at the time of hospital admission was also considered (7). Time-to-measurement of the biomarkers was also added to all multivariate models to assess for possible confounding.
Results
Patient population and IGF1 and IGFBP3 measurements
From January 1999 to March 2009, 44 111 consecutive ICU admissions were screened for possible inclusion (Fig. 1 ). In total, 2397 patients were consented, enrolled, and analyzed for the current study. Five hundred and thirty-one patients (356 controls and 175 cases) had plasma drawn within the target windows around ICU admission or development of ARDS, as described above. Among the 356 controls, 104 (29%) had blood samples drawn on the day of admission to the ICU (day 0); 239 (67%) had blood drawn on day 1 of ICU admission (Fig. 2, top) . Among the 175 ARDS cases, 72 (41%) had blood samples drawn on day 0 of ARDS and 90 (51%) had blood samples drawn on day 1 of ARDS ( Fig. 2, bottom) . Of these 175 case samples, 129 (73.7%) were also drawn within the first 2 days of ICU admission, as in the control group; the onset of ARDS was delayed from ICU admission in the remaining 46 case patients. Plasma measurement of IGF1 and IGFBP3 was successful in 520 and 526 patients respectively.
Excluded patients were compared with tested patients across the spectrum of baseline variables (Table 1) . Due to study design, ARDS cases were more likely to have plasma drawn within the target window, because those patients developing ARDS beyond ICU admission could be captured again with blood drawn around ARDS day 0. Comparing tested and excluded patients, the groups differed significantly in age, BMI, and APACHE III score (Table 1) . After stratifying by ARDS case status to adjust for the higher rate of ARDS cases among patients with available plasma, the differences in age and BMI were seen only in controls, and not among ARDS cases. However, the difference in APACHE III score persisted in both groups.
IGF1 and IGFBP3 levels were strongly positively correlated with each other (Spearman coefficient (r), 0.68, P!0.0001). Both IGF1 and IGFBP3 were negatively correlated with age (rZK0.14, PZ0.0010; rZK0.20, P!0.0001 respectively), consistent with the known parallel decline in GH with age (9, 18) . Both IGF1 and IGFBP3 were also positively correlated with BMI (rZ0.16, PZ0.0006; rZ0.20, P!0.0001 respectively). Table 2) . Because of the strong correlation between IGF1 and IGFBP3 levels, there was evidence of collinearity when both were included in the same multivariable model. Thus, separate models were used to assess each biomarker to avoid the effect of collinearity on the parameter estimates. In unadjusted logistic regression models, higher IGF1 was associated with lower odds of ARDS (odds ratio (OR), 0.53; 95% confidence interval (CI), 0.41-0.70; P!0.0001). The same was true for IGFBP3 (OR, 0.58; 95% CI, 0.43-0.78; PZ0.0003). In multivariable models, this relationship persisted for both IGF1 and IGFBP3 (Table 3 ). The other covariates significant in the models to the P!0.1 level were age, APACHE III score, direct pulmonary injury, sepsis, trauma, diabetes, and the need for red cell transfusion. There was no significant association between the ratio of IGF1 to IGFBP3 (IGF1/IGFBP3) and ARDS case status in either unadjusted or adjusted models. Interaction terms for age and BMI with biomarker levels were not significant. Results were unchanged in the subset of patients with direct pulmonary injury as the etiological risk factor for ARDS. When time-to-measurement was included in the models, it was found to be significant (OR, 0.49; 95% CI, 0.34-0.71). This finding implies that the investigators were more successful in recruiting ARDS cases earlier in their course, compared with controls. This is likely a corollary to the finding described above, due to study design, that patients with ARDS were more likely to have plasma samples available for analysis than controls. However, the inclusion of the time variable had no significant effect on the covariates found to be significant in the multivariable model, nor did it affect the magnitude of the parameter estimates or their P values. Therefore, time-to-measurement was not thought to be a confounder and was not included in the final refit models.
Total IGF1 and IGFBP3 and association with mortality in ARDS cases
Baseline characteristics among the ARDS cases are shown in Table 4 . Of the 175 ARDS cases, 97 (55%) survived and 78 (45%) did not. Survivors were significantly younger than non-survivors and had higher BMIs. Survivors also had significantly lower severity of illness. No patients died who had trauma as their risk factor for ARDS.
IGF1 and IGFBP3 levels were significantly lower in non-survivors than in survivors (Table 4 ). In unadjusted Cox proportional hazards model, IGF1 was negatively associated with hazard of 60-day mortality (hazard ratio (HR), 0.62; 95% CI, 0.46-0.84; PZ0.002). Similarly, IGFBP3 was negatively associated with hazard of death (HR, 0.63; 95% CI, 0.46-0.86; PZ0.003). In multivariable models, this relationship persisted for both IGF1 and IGFBP3 (Table 5 ). Age and APACHE III score were also significant in the Cox models for both biomarkers. There was no significant association between IGF1/IGFBP3 and mortality. Interaction terms for age and BMI with biomarker levels were not significant. Results were unchanged in the subset of patients with direct pulmonary injury as the etiological risk factor for ARDS. When the time-to-measurement variable was included, it was not found to be significant in any model, nor did it appear to be a confounder. (19) (20) (21) (22) (23) . Although fibroproliferation in ARDS was long thought to be a late event based on clinical and histological features, there has been increasing recognition that the initial activating events, including fibroblast activation and collagen turnover, occur very early in the course of ARDS (19, 20) . In several studies, circulating markers have shown parallel alterations with markers measured in BAL fluid. For instance, elevated levels of hepatocyte growth factor were measured in both plasma and pulmonary edema fluid early in the course of acute lung injury, and this correlated with mortality (19) . Similarly, type III procollagen peptide was shown to be elevated in both serum and BAL fluid in acute lung injury and/or ARDS patients compared with controls (20, 21) .
Previous studies have identified significant elevations in IGF1 and IGFBP3 as measured in BAL fluid very early in the course of ARDS (13) . The current study, however, shows decreased circulating levels of IGF1 and IGFBP3 in early ARDS compared with controls. Thus, there may be an inverse association between circulating and lung compartment levels of IGF1 and IGFBP3. This mimics findings in bronchopulmonary dysplasia in which lung IGF1 levels are increased while circulating levels are decreased (10) . Alternatively, IGF1 may be regulated entirely differently in the lung and systemic compartments, and decreased circulating levels of IGF1 and IGFBP3 as markers of GH resistance may thus merely be markers of protein and muscle breakdown with resulting increased susceptibility for infection or delay in recovery. Lower circulating levels of IGF1 and IGFBP3 have been observed in chronically ill patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD), and levels were positively correlated with measures of lung function (FEV 1 ) and respiratory muscle function (maximal inspiratory pressure) respectively (23, 24) .
In a study on COPD patients hospitalized for acute exacerbation, plasma IGF1 levels on day 1 of admission were found to be decreased compared with healthy elderly controls (25) . Levels increased during hospitalization with treatment of the exacerbation, but levels on day 15 were still significantly lower than in controls. IGF1 levels did not appear to be merely an alternative measure of inflammation, however, as levels of inflammatory cytokines (TNF-a, IL1b, IL6, and IL8) were not correlated with IGF1 levels. One additional finding was that patients with emphysema had even lower plasma IGF1 levels than those of COPD patients with chronic bronchitis. This may be relevant to the current study as it associates IGF1 with parenchymal lung disease, as opposed to airways disease and inflammation in the absence of significant parenchymal abnormalities.
The role of IGF1 in diaphragmatic muscle has also been studied in relation to acute respiratory failure in the setting of severe sepsis, as well as with the use of mechanical ventilation (26, 27) .
In a murine model of lipopolysaccharide-induced sepsis, IGF1 expression in diaphragmatic myocytes was found to be increasingly suppressed from 48 to 96 h after lipopolysaccharide injection (26) . IGF1 levels also showed negative correlation with the amount of myofiber injury in the diaphragm, suggesting a protective effect of IGF1 on myofibers during sepsis (26) . A second study compared IGF1 expression in the diaphragmatic muscle of rabbits treated with controlled mechanical ventilation (complete diaphragm muscle inactivity) with assisted mechanical ventilation (partial maintenance of neural activation and mechanical Table 5 Cox proportional hazards models for association of IGF1 and IGFBP3 levels with hazard of 60-day mortality. loading) (27) . The authors observed significantly reduced IGF1 mRNA levels with controlled mechanical ventilation, decreasing expression by 65%. This corresponded to significant myofibrillar disarray. No change in IGF1 mRNA was seen with assisted mechanical ventilation alone.
In humans, studies in COPD patients have shown that local IGF1 production within the muscle is important for stimulating muscle growth and repair and decreased IGF1 may be an important factor in the development of skeletal muscle weakness (28, 29) . Specifically, IGF1 levels were found to be similar in outpatients with stable COPD and COPD patients hospitalized for acute exacerbation (both compared with healthy elderly controls) (28) . However, peripheral muscle force was positively correlated with systemic IGF1 levels and pulmonary functions, suggesting possible involvement of IGF1 in the development of peripheral muscle weakness (28) . A similar study showed that IGF1 mRNA expression in vastus lateralis muscle biopsies was significantly decreased in COPD patients (29) .
Despite the apparent diagnostic implications of our findings in ARDS, the data presented in the current study also raise the question of whether normalizing IGF1 and IGFBP3 could confer any direct therapeutic benefits and thus provide opportunities for further research in the field. Caution must be taken in making the therapeutic leap, however, given previous results of treating critically ill adults with recombinant human GH (rhGH) in an effort to correct the negative nitrogen balance of critical illness (12) . In this well-known study, mortality was significantly increased in patients receiving rhGH treatment, and multiple-organ failure and septic shock or uncontrolled infection were disproportionately represented as causes of death among the treated patients. Nitrogen balance was improved, however, but this did not correlate with decreased duration of mechanical ventilation, ICU stay, or hospital stay, nor did it correlate with increases in IGF1 concentrations. The low IGF1 and IGFBP3 levels seen in this study may reflect GH resistance and thus may explain the lack of efficacy of the rhGH treatment in the study. Although respiratory failure was one diagnosis for inclusion in the study, the remaining diagnostic groups were surgical, thus making this study poorly generalizable to the medical ICU population.
GH levels on ICU admission were also found to predict mortality in a study of septic patients (30) . Interestingly, in this study, IGF1 and IGFBP3 levels were also noted to be low, as in our study, but levels did not differ by severity of illness or between survivors and nonsurvivors, and levels were not predictive of mortality in multivariable models. The latter differs vastly from our study, particularly since sepsis and septic shock patients made up a large proportion of our study population. This again supports the view that IGF1 may have a specific role in ARDS, beyond that of general critical illness.
Finally, therapeutic use of IGF1 has been attempted in rats under hypoxic conditions, again relevant to the current study's patient population (31) . Based on the known anabolic effects of IGF1 demonstrated in animals in a catabolic state, recombinant human IGF1 (rhIGF1) was infused along with total parental nutrition (TPN) in rats under normoxic vs hypoxic (F i O 2 of 0.10) conditions, and nitrogen balance and body weight were compared to similar animals given TPN alone. Nitrogen balance was corrected in hypoxic rats receiving rhIGF1, but they had no significant change in body weight, compared to hypoxic rats not receiving rhIGF1 who were observed to have a drop in body weight. In normoxic rats receiving rhIGF1, however, body weight increased significantly more than in the hypoxic rats. This study thus shows that IGF1 is indeed anabolic in normoxic rats, but this anabolic effect is tempered in animals made catabolic by exposure to hypoxia. This may be one reason why, in the current study, the ARDS (and thus hypoxemic) patients with lower IGF1 levels had higher mortality than those with higher IGF1 levels.
There are several limitations to this study. We did not assess GH in this study, but GH has been well documented to be elevated in critical illness and the sepsis spectrum in particular, and may be independently associated with outcome, as described above (12, 30) . We focused on IGF1 and IGFBP3 that are downstream of GH, and low levels of that may reflect GH resistance in view of the elevated GH described in other studies of the critically ill. We measured biomarkers at a single point in time, early in the course of critical illness and ARDS, and thus we were not able to characterize changes in IGF1 and IGFBP3 over time. IGF1 and IGFBP3 do not exhibit significant diurnal variation, however, making the random timing of blood draws a negligible factor. We also did not adjust for dietary factors as we had no information on preadmission diet, and most intubated, critically ill patients are not fed at the time of ICU admission around which our samples were drawn. We did not obtain BAL fluid for biomarker analyses, and therefore, we were unable to assess the simultaneous activity of the IGF pathway in circulation and lung.
Selection bias must be considered given the difficulty in enrolling all eligible patients within the first 48 h of ICU admission or ARDS, thus resulting in only about a quarter of patients having plasma drawn during this window. This is a common difficulty encountered in clinical critical care research, and it is possible that patients with plasma drawn during this early window differ from those in whom plasma was not obtained. We analyzed clinical characteristics by participation (Table 1 ) and multivariable models adjusted for the variables that differed among participants. Given our robust findings, any residual selection bias would likely affect generalizability rather than the internal validity of the study. This study has many strengths, most importantly that this is a large, well-characterized, prospectively enrolled cohort of patients at risk for ARDS. We used AECC guidelines for defining ARDS case status, a standard measure that limits misclassification in the absence of any 'gold standard' for ARDS diagnosis short of surgical lung biopsy. Biomarker measurements were made using state-of-the-art methodology by personnel blinded to patient case status and to the underlying hypothesis of the study. Assay variability was minimal, and although assay errors cannot be excluded, such errors would result in random misclassification, biasing toward the null.
In summary, the findings in this study suggest an important role for the IGF pathway early in ARDS, as well as in predicting death among ARDS cases. Specifically, IGF1 and IGFBP3 may be protective in critical illness and development of ARDS. ARDS encompasses the systemic alterations of critical illness, and the injury and repair within the respiratory system. Thus, our findings may reflect a complex interplay of the effects of critical illness on the IGF/GH axis, the subsequent effects of critical illness and mechanical ventilation on IGF1 as it affects diaphragmatic function, and fibroproliferation in the lung compartment. Full elucidation of a potentially causal role of IGF1 and IGFBP3 would have important clinical implications, but this will require further mechanistic studies.
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